Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.103.50 CHF
Change Today -15.60 / -13.10%
Volume 592.1K
BSLN On Other Exchanges
SIX Swiss Ex
As of 1:38 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

basilea pharmaceutica-reg (BSLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/26/15 - SFr.139.30
52 Week Low
10/16/14 - SFr.79.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

basilea pharmaceutica-reg (BSLN) Related Businessweek News

No Related Businessweek News Found

basilea pharmaceutica-reg (BSLN) Details

Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company in Switzerland, China, and internationally. The company focuses on the discovery, development, and commercialization of pharmaceutical products in the therapeutic areas of bacterial and fungal infections, and oncology. It offers Toctino, a therapy for the treatment of adult patients with severe chronic hand eczema, who do not respond to potent topical corticosteroids; and Ceftobiprole, a bactericidal antibiotic for the treatment of hospital and community-acquired pneumonia under the brand name of Zevtera. The company is also developing Isavuconazole, an antifungal drug for the treatment of invasive fungal infections, which is under regulatory review by the European Medicines Agency and the U.S. Food and Drug Administration; BAL30072, a monosulfactam antibiotic with bactericidal activity against multidrug-resistant gram-negative bacteria under Phase I clinical development; and BAL101553, a small-molecule anti-cancer drug in Phase IIa clinical development. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

230 Employees
Last Reported Date: 02/12/15
Founded in 2000

basilea pharmaceutica-reg (BSLN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.0M
Compensation as of Fiscal Year 2014.

basilea pharmaceutica-reg (BSLN) Key Developments

Basilea Pharmaceutica AG - Special Call

To discuss top line results from the phase 3 ACTIVE study

Basilea Reports Topline Results of Isavuconazole Phase 3 Study in Candidemia and Other Invasive Candida Infections

Basilea Pharmaceutica Ltd. announced topline results from the phase 3 ACTIVE study. The randomized double-blind study evaluated the efficacy and safety of intravenously (i.v.) and orally administered isavuconazole versus a regimen of i.v. caspofungin followed by oral voriconazole, as a potential treatment for adults with candidemia and other invasive Candida infections. The results showed that the study did not meet the primary objective of demonstrating non-inferior efficacy of isavuconazole versus the study comparator at the end of i.v. therapy within the pre-specified non-inferiority margin. The overall response rates at two weeks after treatment were, however, comparable between the two treatment groups. Overall response at two weeks after treatment was the key secondary endpoint of the study. In addition, the secondary endpoint of all-cause mortality was comparable at study day 14 and day 56 in both treatment groups. The overall safety profile of isavuconazole was similar to caspofungin and consistent with safety data seen in the previously reported phase 3 studies. The overall response at the end of i.v. treatment in the modified intent-to-treat population (mITT; N=400)* was 60.3% in the isavuconazole treatment group and 71.1% in the caspofungin group with an adjusted treatment difference of -10.8% (95% CI; -19.9%, -1.8%). The lower bound of the 95% confidence interval (CI) of the treatment difference between isavuconazole and caspofungin exceeded the pre-specified non-inferiority margin of -15%.

Basilea Pharmaceutica AG Initiates Phase 1/2a Oncology Study with Oral Formulation of Tumor Checkpoint Controller BAL101553

Basilea Pharmaceutica AG announced the start of a clinical phase 1/2a study with an oral formulation of its anti-cancer drug candidate BAL101553. BAL101553 is a microtubule-destabilizing small molecule, acting as tumor checkpoint controller (TCC) as it promotes tumor cell death through activation of an important checkpoint in cell proliferation. The primary objective of the phase 1 study is to determine the maximum tolerated dose (MTD) in adult patients with advanced or recurrent solid tumors who have failed standard therapy or for whom no effective standard therapy is available. BAL101553 capsules will be administered once daily. A subsequent phase 2a extension of the study is planned to further evaluate the safety, tolerability and the pharmacokinetic profile of daily oral BAL101553 at the MTD, and to assess its anti-tumor activity. Furthermore, biomarkers will be explored in both the phase 1 and phase 2a parts of the study to determine their potential utility in identifying patients who are most likely to respond to treatment. An intravenous (i.v.) formulation of BAL101553 is currently being investigated in a separate phase 2a clinical study in cancer patients with advanced solid tumors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSLN:SW SFr.103.50 CHF -15.60

BSLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSLN.
View Industry Companies

Industry Analysis


Industry Average

Valuation BSLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.5x
Price/Book 22.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BASILEA PHARMACEUTICA-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at